Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi American Depositary Shares (NASDAQ: SNY) represent an R&D driven, AI-powered biopharma company that regularly issues news on its medicines, vaccines, pipeline programs, and strategic initiatives. Company communications describe a focus on immunology, autoimmune diseases, rare diseases, diabetes, respiratory conditions, and infectious disease prevention, which generates a steady flow of clinically and commercially relevant updates.
News about Sanofi often covers clinical trial milestones, regulatory decisions, and collaborations. Recent examples include collaborations with Dren Bio on next-generation B-cell depletion therapies for autoimmune disease, a collaboration and license agreement with EVOQ Therapeutics around NanoDisc technology for autoimmune conditions, and a partnership with Revvity to support development and validation of a type 1 diabetes autoantibody assay for early detection. Sanofi also reports on RSV prevention with BEYFORTUS, COPD care initiatives with Viz.ai and Regeneron, and progress in alpha-1 antitrypsin deficiency emphysema.
Investors and healthcare observers will also find corporate and strategic news, such as Sanofi’s intention to invest at least $20 billion in the United States through 2030, the opening of new flagship offices in Morristown, New Jersey, and the planned acquisition of Blueprint Medicines to expand its rare immunological disease portfolio. Additional releases highlight community-focused programs like the Healthy Futures Solution Fund and the expansion of the Insulins Valyou Savings Program in the US.
This SNY news page aggregates these announcements, providing a single place to follow Sanofi’s clinical data readouts, regulatory updates, partnerships, acquisitions, access and affordability initiatives, and other developments that shape the company’s role in global healthcare.
Regeneron and Sanofi announced positive Phase 3 trial results for Dupixent (dupilumab) 300 mg weekly in treating eosinophilic esophagitis (EoE), a chronic inflammatory disease. The trial showed a 64% reduction in disease symptoms after 24 weeks compared to placebo, with 59% of Dupixent patients achieving histological remission. The safety profile was consistent with previous studies. Regulatory filings are expected in 2022. EoE affects around 160,000 patients in the U.S., highlighting the potential market for Dupixent in this indication.
Summary not available.
Sanofi announced a collaboration with Breast International Group (BIG), EORTC, and AFT to initiate the Phase 3 AMEERA-6 study, focusing on the oral selective estrogen receptor degrader (SERD) amcenestrant for estrogen receptor-positive breast cancer in patients unable to continue aromatase inhibitor therapy. The trial aims to evaluate amcenestrant's efficacy and safety against tamoxifen. Sanofi will sponsor the study, which is crucial for providing alternatives in adjuvant therapy to combat disease recurrence.
Sanofi and Merck have announced that Vaxelis, the first hexavalent combination vaccine in the U.S., is now available. This vaccine protects against six diseases: diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B, administered in three doses to children aged 6 weeks to 4 years. The vaccine aims to reduce the number of shots children need, improving vaccination coverage. Vaxelis has been included in the CDC's immunization schedule and will be distributed through various channels. The collaboration reflects a commitment to enhancing pediatric health.
Sanofi has announced a three-year research collaboration with Stanford University School of Medicine, aiming to deepen the understanding of immunology and inflammation. The partnership will explore autoimmune diseases and inflammatory conditions, with funding for up to three joint programs annually. Initial projects will focus on type 2 inflammation, T cell mechanisms in autoimmunity, and immune-related adverse events. This collaboration strengthens Sanofi's commitment to research and innovation within immunoscience.
Sanofi has partnered with Moderna to manufacture up to 200 million doses of its COVID-19 vaccine, utilizing its Ridgefield, NJ facility starting September 2021. This represents Sanofi's third manufacturing commitment in response to the pandemic, having previously supported BioNTech and Johnson & Johnson. The company is also developing its COVID-19 vaccine candidates in collaboration with GSK and Translate Bio. Sanofi aims to enhance global vaccine supply while continuing its internal vaccine development efforts.
On April 7, 2021, Sanofi announced the creation of Sanofi Global Health, a new nonprofit unit aimed at enhancing access to essential medicines in 40 lower-income countries. The initiative will provide 30 medicines across various therapeutic areas, alongside support for healthcare professionals. Additionally, Sanofi plans to donate 100,000 vials of treatments annually for rare diseases. The company also committed to reducing greenhouse gas emissions by 55% by 2030 and implementing zero plastic packaging for vaccines by 2027, while promoting diversity within its workforce.
The FDA has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) after one to three prior treatments. The approval is based on the Phase 3 IKEMA study, which demonstrated a 45% reduction in disease progression or death risk. Sarclisa now has two FDA-approved combinations for RRMM. Despite challenges in treating relapsed MM, the approval positions Sarclisa as a potential standard of care, enhancing its market potential.
Biond Biologics has signed an exclusive worldwide license agreement with Sanofi (SNY) for the development of BND-22, a humanized IgG4 antibody aimed at treating solid tumors. Biond will receive a $125 million upfront payment and potentially over $1 billion in milestones and royalties. BND-22 targets the inhibitory ILT2 receptor and has shown promising preclinical results by activating immune responses against tumors. The first-in-human phase 1a study is set to start by mid-2021, with Sanofi overseeing later clinical development.
Sanofi and the Parkinson's Foundation are collaborating to enhance genetic testing and counseling for Parkinson's disease patients in the U.S. Over two years, Sanofi will invest $1 million in the PD GENEration: Mapping the Future of Parkinson's Disease initiative. The study aims to improve understanding of genetic mutations related to Parkinson's, facilitating patient access to clinical trials. Initial results show a higher prevalence of genetic links to the disease, with plans to enroll 15,000 participants.